166.94MMarket Cap-1.66P/E (TTM)
2.5200High2.4100Low246.21KVolume2.5200Open2.5200Pre Close602.91KTurnover0.51%Turnover RatioLossP/E (Static)67.59MShares19.050052wk High0.51P/B118.80MFloat Cap2.320052wk Low--Dividend TTM48.10MShs Float85.0000Historical High--Div YieldTTM4.37%Amplitude0.0300Historical Low2.4480Avg Price1Lot Size
Perspective Therapeutics Stock Forum
Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Monday, 17th March at 7:00 am
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first...
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Friday, 24th January at 7:00 am
• Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212...
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
Wednesday, 22nd January at 7:00 am
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated in...
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
No comment yet